Patents Assigned to Research Corporation Technologies, Inc.
  • Patent number: 6140480
    Abstract: The present invention provides fluorescent nucleosides carrying polycyclic aromatic hydrocarbons such as anthracene, phenanthrene, pyrene stilbene, tetracene or pentacene. The subject nucleosides may be synthesized using a C-glycosidic bond formation method employing organocadium or organozinc derivatives of the aromatic compounds and coupling with a 1-.alpha.-chlororibose or deoxyribose synthon. The .alpha.-anomers of the coupling reaction may be epimerized to the .beta.-anomers by acid-catalyzed equilibration. The fluorescent nucleosides act as DNA or RNA base analogs and can be incorporated into nucleic acids. Resultant fluorescently tagged nucleic acids are useful as probes for target nucleic acids in tissues, solutions or immobilized on membranes.
    Type: Grant
    Filed: September 17, 1999
    Date of Patent: October 31, 2000
    Assignee: Research Corporation Technologies, Inc.
    Inventor: Eric T. Kool
  • Patent number: 6133261
    Abstract: The invention provides a therapeutic method for treating or preventing stroke and other ischemic disorders, as well as novel compounds and pharmaceutical compositions useful for carrying out such methods.
    Type: Grant
    Filed: July 15, 1998
    Date of Patent: October 17, 2000
    Assignee: Research Corporation Technologies, Inc.
    Inventor: Robert H. Harris
  • Patent number: 6124091
    Abstract: The present invention provides a partial cDNA corresponding to an RNA containing double stranded regions (R-RNA), which, when transcribed in vitro, gives rise to an RNA transcript that activates PKR. An approximately 226-252 bp nucleotide (nt) sequence responsible for activation of PKR (the activation sequence) has been identified within the cDNA and isolated. Antisense oligonucleotides corresponding to specific portions of the 252 nt cDNA fragment stimulate proliferation of different cells in culture. Various portions of the cDNA or R-RNA may also be used to inhibit cell proliferation in cell cultures.The present invention further provides pharmaceutical compositions comprising the subject nucleic acid fragments and oligonucleotides. Kits which comprise at least one of the subject isolated nucleic acid molecules or oligonucleotides and a pharmaceutically acceptable carrier are also provided.
    Type: Grant
    Filed: May 30, 1997
    Date of Patent: September 26, 2000
    Assignee: Research Corporation Technologies, Inc.
    Inventor: Raymond A. Petryshyn
  • Patent number: 6110925
    Abstract: The present invention is directed to anti-bacterial and anti-tumor agents and the synthesis thereof.
    Type: Grant
    Filed: August 6, 1998
    Date of Patent: August 29, 2000
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Robert M. Williams, Chenguang Yuan
  • Patent number: 6106834
    Abstract: A method for the prevention or reversal of transplant rejection, or for therapy for autoimmune diseases, is provided comprising administering compounds such as monoclonal antibodies, that bind specifically to one or more preselected CD45R leukocyte antigens, including the CD45RB epitope.
    Type: Grant
    Filed: September 18, 1996
    Date of Patent: August 22, 2000
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Andrew I. Lazarovits, Sibrand Poppema
  • Patent number: 6090380
    Abstract: Pooled human immunoglobulin may be administered orally to rheumatoid arthritis patients to treat the rheumatoid arthritic condition of those patients. Oral administration of pooled human immunoglobulin can result in significant clinical improvement in the level of disease activity in patients with rheumatoid arthritis.
    Type: Grant
    Filed: May 22, 1995
    Date of Patent: July 18, 2000
    Assignee: Research Corporation Technologies, Inc.
    Inventor: Richard Weisbart
  • Patent number: 6040422
    Abstract: The present invention is directed to a process for forming a peptide bond between a first amino acid having a free amino group and a protected carboxy group and a second amino acid or between a peptide having a free amino group and a blocking carboxy group with a second amino acid which comprises (a) reacting the second amino acid of the formula: ##STR1## with a fluoroformamidinium salt of the formula: ##STR2## and (b) reacting the product of (a) with the first amino acid or peptide.
    Type: Grant
    Filed: January 5, 1998
    Date of Patent: March 21, 2000
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Louis A. Carpino, Ayman Ahmed El-Faham
  • Patent number: 6024957
    Abstract: Compounds and methods are described for the differential inhibition of tyrosine phosphorylation of phospholipase C-.gamma.1 for the prevention or reversal of transplant rejection as well as therapy for autoimmune diseases. Methods for the treating or preventing tissue or organ transplant rejection and methods for treating an autoimmune disease comprising the administration of monoclonal antibodies that specifically bind to the CD45RB epitope of the CD45RB isoform are disclosed.
    Type: Grant
    Filed: April 18, 1995
    Date of Patent: February 15, 2000
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Andrew I. Lazarovits, Sibrand Poppema
  • Patent number: 6017883
    Abstract: The present invention relates to the identification, purification and characterization of novel factors which inhibit phagocyte activation, such as inhibiting polymorphonuclear neutrophil chemotaxis, degranulation and superoxide production. Disclosed are natural peptides purified from the bronchial environment and a variety synthetic peptides and analogues designed to have enhanced or longer-lasting phagocyte-inhibiting activity. The peptides and compositions of the present invention are contemplated for use in modulating inflammatory responses in a number of clinical settings, such as in the treatment of asthma, bronchitis, acute lung injury, rheumatoid arthritis, psoriasis, dermatitis and inflammatory bowel disease, and for use as anti-proliferative agents such as in the treatment of cancer.
    Type: Grant
    Filed: March 3, 1998
    Date of Patent: January 25, 2000
    Assignee: Research Corporation Technologies, Inc.
    Inventor: J. Allen D. Cooper, Jr.
  • Patent number: 6015543
    Abstract: The present invention relates to a class of compounds having affinity for certain cancer cells, e.g. lung carcinomas, colon carcinomas, renal carcinomas, prostate carcinomas, breast carcinomas, malignant melanomas, gliomas, neuroblastomas and pheochromocytomas. The compounds of the present invention can also bind with high specificity to cell surface sigma receptors and can therefore be used for diagnostic imaging of any tissue having an abundance of cells with sigma receptors. The present invention provides such compounds as agents for diagnostic imaging and for detecting and treating tumors containing the cancer cells described above.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: January 18, 2000
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Christy S. John, Jesse Baumgold, John G. McAfee, Terry Moody, Wayne Bowen
  • Patent number: 5993777
    Abstract: The present invention relates to a class of compounds having affinity for certain cancer cells, e.g. lung carcinomas, colon carcinomas, renal carcinomas, prostate carcinomas, breast carcinomas, malignant melanomas, gliomas, neuroblastomas and pheochromocytomas. The compounds of the present invention can also bind with high specificity to cell surface sigma receptors and can therefore be used for diagnostic imaging of any tissue having an abundance of cells with sigma receptors. The present invention provides such compounds as agents for diagnostic imaging and for detecting and treating tumors containing the cancer cells described above.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 30, 1999
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Christy S. John, Jesse Baumgold, John G. McAfee, Terry Moody, Wayne Bowen
  • Patent number: 5989916
    Abstract: The present invention relates to the direct quantitative determination of cholesterol and involves the formation of a spectrophotometrically active product of cholesterol obtained by contacting cholesterol with an acyl compound and a perchlorate effective to form the spectrophotometrically active product.
    Type: Grant
    Filed: February 12, 1998
    Date of Patent: November 23, 1999
    Assignee: Research Corporation Technologies, Inc.
    Inventor: Neil Purdie
  • Patent number: 5990388
    Abstract: The invention provides a method for imparting resistance in animals to viruses, and in plants to viruses and viroids, that express double-stranded RNA-like structures (dsRNAs). This method enables the binding of pathogenic dsRNAs during the infection process by expression of dsRNA-binding protein in transgenic animal and plant hosts, thus interrupting the infection cycle and inhibiting disease. The presence of a dsRNA-binding protein in a transgenic host renders the transgenic host resistant to the phenotypic symptoms of viral infection and/or decreased pathogen replication. Accordingly, the present invention provides a genetically engineered animal and plant, stably transformed to express a dsRNA-binding protein, such that the transgenic host displays resistance to virus and/or viroid challenge.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 23, 1999
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Don Allen Roth, Jeffrey Olaf Langland
  • Patent number: 5976522
    Abstract: Disclosed is a substantially pure antibody which specifically binds a LCF polypeptide and methods of using such antibodies.
    Type: Grant
    Filed: December 29, 1995
    Date of Patent: November 2, 1999
    Assignee: Research Corporation Technologies, Inc.
    Inventors: David M. Center, William W. Cruikshank, Hardy Kornfeld
  • Patent number: 5965360
    Abstract: The present invention is directed towards the diagnosis of malignant cancer by detection of the mts-1 mRNA or the mts-1 protein, encoded by the mts-1 gene. The present invention contemplates the use of recombinant mts-1 DNA and antibodies directed against the mts-1 protein to diagnose the metastatic potential of several types of tumor cells, including, for example, thyroid, epithelial, lung, liver and kidney tumor cells. The present invention is also directed to mammalian cell lines and tumors with high and low metastatic potential which have been developed to serve as useful model systems for in vitro and in vivo anti-metastasis drug screening.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: October 12, 1999
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Sayeeda Zain, Eugene Lukanidin
  • Patent number: 5965120
    Abstract: Disclosed is a substantially pure antibody which specifically binds a LCF polypeptide and methods of using such antibodies.
    Type: Grant
    Filed: December 29, 1995
    Date of Patent: October 12, 1999
    Assignee: Research Corporation Technologies, Inc.
    Inventors: David M. Center, William W. Cruikshank, Hardy Kornfeld
  • Patent number: 5958404
    Abstract: A method of treating a disease is provided that results from a deficiency of a biological factor which comprises administering to a mammal Sertoli cells and cells that produce the biological factor. A method of treating diabetes mellitus is carried out by transplanting pancreatic islet of Langerhans cells in conjunction with Sertoli cells to create an immunologically privileged site. A method of creating an immunologically privileged site and providing cell stimulatory factors in a mammal for transplants is also carried out. A method of co-localizing islet cells with Sertoli cells and the use of the co-localized product for treating diabetes mellitus is further provided. Further described is a method of creating systemic tolerance to foreign antigens. A method of enhancing the viability, maturation, proliferation of functional capacity of cells in tissue culture is also provided. In addition, a pharmaceutical composition comprising Sertoli cells and cells that produce a biological factor is provided.
    Type: Grant
    Filed: June 7, 1996
    Date of Patent: September 28, 1999
    Assignee: Research Corporation Technologies, Inc.
    Inventor: Helena P. Selawry
  • Patent number: 5958624
    Abstract: The present invention provides mesostructural metal oxide materials that can be employed in lithium ion rechargeable batteries as intercalation electrodes. The mesostructural metal oxide materials of the present invention maintain their structural integrity during intercalation, are reversible and exhibit increased electrochemical capacity. The use of such mesostructural metal oxides in rechargeable batteries is also described herein.
    Type: Grant
    Filed: December 18, 1997
    Date of Patent: September 28, 1999
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Roger E. Frech, Xulong Zhang
  • Patent number: 5935805
    Abstract: The present invention is directed to the determination of unconjugated and unbound bilirubin in a sample.
    Type: Grant
    Filed: November 28, 1997
    Date of Patent: August 10, 1999
    Assignee: Research Corporation Technologies, Inc.
    Inventor: Charles E. Ahlfors
  • Patent number: 5920394
    Abstract: An apparatus and method for directing a light beam onto a moving article. The apparatus comprises first and second mirrors for directing the light beam in an adjustable direction, first and second motors connected to the first and second mirrors to move those mirrors, and a tracking system connected to the first and second motors to operate those motors to move the first and second mirrors to maintain the light beam directed at the article as the article moves. Preferable, the tracking system includes coarse and fine tracking subsystems. The coarse tracking subsystem is used to operate the motors to move the mirrors to direct the light beam approximately onto the article, and the fine tracking subsystem is used to operate the motors to operate the mirrors to direct the light beam substantially directly onto the article.
    Type: Grant
    Filed: August 30, 1996
    Date of Patent: July 6, 1999
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Daniel Gelbart, Michel G. Laberge